Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-15

Immunome (IMNM)

CEO Clay Siegall was paid $7,682,601 in fiscal year 2025, ↓ down 16.7% from fiscal year 2024 (SEC filing 0001140361-26-016685 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,682,601 ↓
Clay Siegall total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
98.44%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

IMNM's next annual pay disclosure, estimated April 24, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Clay Siegall$735,000—$0$6,272,810$661,500$0$13,291$7,682,601
President, Chief Executive Officer and Chairman of the Board
Max Rosett472,500—01,623,090278,8000411,1672,785,557
Chief Financial Officer
Robert Lechleider530,300—01,897,525307,600012,1932,747,618
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Clay Siegall$7,682,601$9,226,774$14,866,831↓ −1,544,173
Max Rosett2,785,557———
Robert Lechleider2,747,618———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Immunome's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper IMNM reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against IMNM
3 companies name IMNM as a compensation peer

The list of companies that name IMNM as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Carol SchaferIndependent Director$195,000
Isaac Barchas, J.DLead Independent Director$210,000
James BoylanIndependent Director$190,000
Jean-Jacques BienaimIndependent Director—
Philip WagenheimIndependent Director$175,000
Sandra Swain, M.DIndependent Director$182,500
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jean Jacques BienaimeDirector2026-05-15A5,000$21$103,500CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05D10,00019194,100CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A1,0001919,270CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A3,5001968,110CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A6,00019116,880CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05D500199,720CommonForm 4 ↗
Philip WagenheimDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Sandra M. SwainDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Carol SchaferDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Isaac BarchasDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
James BoylanDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15D60,00000Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15D60,000181,093,800CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15A60,000163,000CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D55,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D14,42021297,917Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D40,58020793,745Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25A55,0009480,150CommonForm 4 ↗
Isaac BarchasDirector2026-06-30D101,050212,134,176Common, indirectForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D16,07223376,728Common, open-market saleForm 4 ↗
Isaac BarchasDirector2026-07-02D75,665221,691,113Common, indirectForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02A55,0009480,150CommonForm 4 ↗
Isaac BarchasDirector2026-07-02D24,33523567,736Common, indirectForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D55,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D16,21423369,031Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D22,71422498,572Common, open-market saleForm 4 ↗
Isaac BarchasDirector2026-07-06D83,094242,003,396Common, indirectForm 4 ↗
Dividend-equivalent accruals2026-07-07—1,092——1 insider, 1 accrual row
Kinney HornCHIEF BUSINESS OFFICER2026-07-07D1,0922527,300CommonForm 4 ↗
Isaac BarchasDirector2026-07-07D16,90624409,125Common, indirectForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-07A1,0921314,109CommonForm 4 ↗
Clay SiegallDirector2026-07-23A360,00000Derivative, Class A CommonForm 4 ↗
Clay SiegallDirector2026-07-23A180,00000RSUForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-23A108,00000Derivative, Class A CommonForm 4 ↗
Sandra G. StonemanCHIEF LEGAL OFFICER & GC2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Sandra G. StonemanCHIEF LEGAL OFFICER & GC2026-07-23A38,25000RSUForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-23A62,50000Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-23A31,25000RSUForm 4 ↗
Philip TsaiChief Technical Officer2026-07-23A38,25000RSUForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-23A54,00000RSUForm 4 ↗
Max RosettChief Financial Officer2026-07-23A94,50000Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-07-23A47,25000RSUForm 4 ↗
Philip TsaiChief Technical Officer2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-07-23A38,25000RSUForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04D90,616252,273,555Common, open-market saleForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04A40,25011426,650CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04D50,36600Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04D40,25000Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04A50,36613650,729CommonForm 4 ↗
Isaac BarchasDirector2026-08-06D20,84026543,090Common, indirectForm 4 ↗
Isaac BarchasDirector2026-08-07D15,24826397,363Common, indirectForm 4 ↗
Isaac BarchasDirector2026-08-10D10,12526263,959Common, indirectForm 4 ↗
Isaac BarchasDirector2026-08-11D62,291261,633,893Common, indirectForm 4 ↗
Isaac BarchasDirector2026-08-12D11,04827301,058CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-09-11A18,00000Derivative, Class A CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-09-11D8,80000CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-09-11D13,20025334,224CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-09-11A18,000124,300CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 60 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jean Jacques BienaimeDirector2026-05-15A5,000$21$103,500CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05D10,00019194,100CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A1,0001919,270CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A3,5001968,110CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A6,00019116,880CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05D500199,720CommonForm 4 ↗
Philip WagenheimDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Sandra M. SwainDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Carol SchaferDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Isaac BarchasDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
James BoylanDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15D60,00000Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15D60,000181,093,800CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15A60,000163,000CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D55,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D14,42021297,917Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D40,58020793,745Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25A55,0009480,150CommonForm 4 ↗
Isaac BarchasDirector2026-06-30D101,050212,134,176Common, indirectForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D16,07223376,728Common, open-market saleForm 4 ↗
Isaac BarchasDirector2026-07-02D75,665221,691,113Common, indirectForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02A55,0009480,150CommonForm 4 ↗
Isaac BarchasDirector2026-07-02D24,33523567,736Common, indirectForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D55,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D16,21423369,031Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D22,71422498,572Common, open-market saleForm 4 ↗
Isaac BarchasDirector2026-07-06D83,094242,003,396Common, indirectForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-07D1,09200Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-07D1,0922527,300CommonForm 4 ↗
Isaac BarchasDirector2026-07-07D16,90624409,125Common, indirectForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-07A1,0921314,109CommonForm 4 ↗
Clay SiegallDirector2026-07-23A360,00000Derivative, Class A CommonForm 4 ↗
Clay SiegallDirector2026-07-23A180,00000RSUForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-23A108,00000Derivative, Class A CommonForm 4 ↗
Sandra G. StonemanCHIEF LEGAL OFFICER & GC2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Sandra G. StonemanCHIEF LEGAL OFFICER & GC2026-07-23A38,25000RSUForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-23A62,50000Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-23A31,25000RSUForm 4 ↗
Philip TsaiChief Technical Officer2026-07-23A38,25000RSUForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-23A54,00000RSUForm 4 ↗
Max RosettChief Financial Officer2026-07-23A94,50000Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-07-23A47,25000RSUForm 4 ↗
Philip TsaiChief Technical Officer2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-07-23A38,25000RSUForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04D90,616252,273,555Common, open-market saleForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04A40,25011426,650CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04D50,36600Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04D40,25000Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-08-04A50,36613650,729CommonForm 4 ↗
Isaac BarchasDirector2026-08-06D20,84026543,090Common, indirectForm 4 ↗
Isaac BarchasDirector2026-08-07D15,24826397,363Common, indirectForm 4 ↗
Isaac BarchasDirector2026-08-10D10,12526263,959Common, indirectForm 4 ↗
Isaac BarchasDirector2026-08-11D62,291261,633,893Common, indirectForm 4 ↗
Isaac BarchasDirector2026-08-12D11,04827301,058CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-09-11A18,00000Derivative, Class A CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-09-11D8,80000CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-09-11D13,20025334,224CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-09-11A18,000124,300CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Max RosettOPTION—————$1,623,090
Clay SiegallOPTION—————6,272,810
Robert LechleiderOPTION—————1,897,525
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Max Rosett$0$0$1,623,0900.0%
Clay Siegall006,272,8100.0%
Robert Lechleider001,897,5250.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Robert LechleiderOption242,00010.6—
Max RosettOption18,12514.4—
Clay SiegallOption533,33412.92—
Max RosettOption91,14616.57—
Max RosettOption8,3661.05—
Robert LechleiderOption133,33412.92—
Max RosettOption126,66712.92—
Clay SiegallOption800,00010.6—
Clay SiegallOption979,4955.91—
Max RosettOption207,00010.6—
Robert LechleiderOption183,3348.73—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is designed to align pay with Company performance and long-term stockholder value creation.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0990,908,4361,442,11631,01498.44%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0998.44%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Isaac Barchas, J.DIndependent · Lead Independent Director · Compensation · Nominating and Corporate Governance (Chair)$75,000$0$135,000$0$0$210,000
Carol SchaferIndependent · Audit (Chair) · Nominating and Corporate Governance60,0000135,00000195,000
James BoylanIndependent · Compensation (Chair) · Nominating and Corporate Governance55,0000135,00000190,000
Jean-Jacques BienaiméIndependent · Audit · Compensation52,5000135,00000187,500
Sandra Swain, M.DIndependent · Audit47,5000135,00000182,500
Philip WagenheimIndependent · Compensation40,0000135,00000175,000
Clay Siegall, Ph.DEmployee director · Board Chair000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$135,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)7,500 / 5,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$330,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$330,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Immunome2025Clay Siegall$735,000$0$6,272,810$661,500$7,682,601

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Immunome in fiscal 2025?
As disclosed, Clay Siegall (President, Chief Executive Officer and Chairman of the Board) was the highest-paid executive at Immunome in fiscal 2025, with total compensation of $7,682,601.
How did shareholders vote on Immunome's executive compensation?
As disclosed, 98.44% of shareholders supported Immunome's executive compensation in the latest say-on-pay vote.
How much does Immunome spend in total on board compensation for fiscal 2025?
As disclosed, Immunome reported total board compensation of $330,000 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Clay SiegallDEF 14A2026-04-240001140361-26-016685Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 7,682,601. Filing ↗machine: r2 · c21 · span 416484–416493
2Section 01, Max RosettDEF 14A2026-04-240001140361-26-016685Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 2,785,557. Filing ↗machine: r4 · c21 · span 424106–424115
3Section 01, Robert LechleiderDEF 14A2026-04-240001140361-26-016685Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 2,747,618. Filing ↗machine: r5 · c21 · span 428410–428419
4Section 03, Max Rosett OPTIONDEF 14A2026-04-240001140361-26-016685Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r4 · c12 · span 422704–422713
5Section 03, Clay Siegall OPTIONDEF 14A2026-04-240001140361-26-016685Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r2 · c12 · span 414755–414764
6Section 03, Robert Lechleider OPTIONDEF 14A2026-04-240001140361-26-016685Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r5 · c12 · span 426795–426804
7Section 07, pay ratio10-K2026-03-030001193125-26-088172Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Isaac Barchas, J.DDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 210,000. Filing ↗machine: t97 · r2 · c9 · span 658329–658508
9Section 08, Carol SchaferDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 195,000. Filing ↗machine: t97 · r3 · c9 · span 660052–660231
10Section 08, James BoylanDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 190,000. Filing ↗machine: t97 · r5 · c9 · span 663792–663971
11Section 08, Jean-Jacques BienaiméDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 187,500. Filing ↗
12Section 08, Sandra Swain, M.DDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 182,500. Filing ↗machine: t97 · r6 · c9 · span 665790–665969
13Section 08, Philip WagenheimDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 175,000. Filing ↗machine: t97 · r7 · c9 · span 667419–667597
14Section 08, Clay Siegall, Ph.DDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 0. Filing ↗
15Section 02, Jean Jacques Bienaime 2026-05-15Form 42026-05-190001221590-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Philip Wagenheim 2026-06-10Form 42026-06-120001405684-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Sandra M. Swain 2026-06-10Form 42026-06-120001908755-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Carol Schafer 2026-06-10Form 42026-06-120001272181-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Isaac Barchas 2026-06-10Form 42026-06-120001808343-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, James Boylan 2026-06-10Form 42026-06-120001953094-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Jean Jacques Bienaime 2026-06-10Form 42026-06-120001221590-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Max Rosett 2026-06-15Form 42026-06-170001994071-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Max Rosett 2026-06-15Form 42026-06-170001994071-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Max Rosett 2026-06-15Form 42026-06-170001994071-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Robert Lechleider 2026-06-25Form 42026-06-290001997584-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Robert Lechleider 2026-06-25Form 42026-06-290001997584-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Robert Lechleider 2026-06-25Form 42026-06-290001997584-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Robert Lechleider 2026-06-25Form 42026-06-290001997584-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Isaac Barchas 2026-06-30Form 42026-07-020001808343-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Isaac Barchas 2026-07-02Form 42026-07-020001808343-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Isaac Barchas 2026-07-02Form 42026-07-020001808343-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Isaac Barchas 2026-07-06Form 42026-07-070001808343-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Kinney Horn 2026-07-07Form 42026-07-090001831215-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Kinney Horn 2026-07-07Form 42026-07-090001831215-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Isaac Barchas 2026-07-07Form 42026-07-070001808343-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Kinney Horn 2026-07-07Form 42026-07-090001831215-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Clay Siegall 2026-07-23Form 42026-07-270001167496-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Clay Siegall 2026-07-23Form 42026-07-270001167496-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Robert Lechleider 2026-07-23Form 42026-07-270001997584-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Sandra G. Stoneman 2026-07-23Form 42026-07-270001831144-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Sandra G. Stoneman 2026-07-23Form 42026-07-270001831144-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Kinney Horn 2026-07-23Form 42026-07-270001831215-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Kinney Horn 2026-07-23Form 42026-07-270001831215-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Philip Tsai 2026-07-23Form 42026-07-270002026600-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Robert Lechleider 2026-07-23Form 42026-07-270001997584-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Max Rosett 2026-07-23Form 42026-07-270001994071-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Max Rosett 2026-07-23Form 42026-07-270001994071-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Philip Tsai 2026-07-23Form 42026-07-270002026600-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Jack Higgins 2026-07-23Form 42026-07-270001993684-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Jack Higgins 2026-07-23Form 42026-07-270001993684-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Kinney Horn 2026-08-04Form 42026-08-060001831215-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Kinney Horn 2026-08-04Form 42026-08-060001831215-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Kinney Horn 2026-08-04Form 42026-08-060001831215-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Kinney Horn 2026-08-04Form 42026-08-060001831215-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Kinney Horn 2026-08-04Form 42026-08-060001831215-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Isaac Barchas 2026-08-06Form 42026-08-100001808343-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Isaac Barchas 2026-08-07Form 42026-08-100001808343-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Isaac Barchas 2026-08-10Form 42026-08-120001808343-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Isaac Barchas 2026-08-11Form 42026-08-120001808343-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Isaac Barchas 2026-08-12Form 42026-08-120001808343-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Jack Higgins 2026-09-11Form 42026-09-150001993684-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Jack Higgins 2026-09-11Form 42026-09-150001993684-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Jack Higgins 2026-09-11Form 42026-09-150001993684-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Jack Higgins 2026-09-11Form 42026-09-150001993684-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
75Section 06, 2026 voteForm 8-K2026-06-120001193125-26-269383Item 5.07 · say-on-pay result. As reported: 98.44% (votes for as printed: 90,908,436). Filing ↗
76Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
77Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
78Section 09b board cost (computed)Computed——Cash 330,000 + equity 0 + all other 0 = 330,000, summed across the director compensation table rows.machine: formula: Σ = 330,000
79Immunome (subject), Section 10b CEO totalDEF 14A2026-04-240001140361-26-016685CEO total compensation as printed in Immunome's own proxy. As printed: 7,682,601. Filing ↗machine: r2 · c21 · span 416484–416493

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.